Home

Viking Therapeutics, Inc. - Common Stock (VKTX)

27.34
-0.83 (-2.96%)
NASDAQ · Last Trade: Jun 27th, 10:34 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close28.17
Open28.00
Bid27.31
Ask27.36
Day's Range27.01 - 28.09
52 Week Range18.92 - 81.73
Volume822,112
Market Cap2.72B
PE Ratio (TTM)-23.77
EPS (TTM)-1.2
Dividend & YieldN/A (N/A)
1 Month Average Volume3,447,803

Chart

About Viking Therapeutics, Inc. - Common Stock (VKTX)

Viking Therapeutics is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company is engaged in advancing a portfolio of drug candidates aimed at addressing diseases with significant unmet medical needs, including non-alcoholic steatohepatitis (NASH) and obesity. Viking’s approach leverages proprietary drug development technologies to design and optimize novel therapeutic compounds, with an emphasis on safety and efficacy. Through its research and clinical trials, the company aims to bring transformative treatments to market that can improve patient outcomes and enhance quality of life. Read More

News & Press Releases

Why This Weight Loss Drug Company's Stock Surged Todayfool.com
Via The Motley Fool · June 26, 2025
3 Growth Stocks I'm Loading Up Onfool.com
Via The Motley Fool · June 26, 2025
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesityinvestors.com
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via Investor's Business Daily · June 25, 2025
What's Going On With Viking Therapeutics Stock On Wednesday?benzinga.com
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via Benzinga · June 25, 2025
My 5 Favorite Dirt Cheap Stocks to Buy Right Nowfool.com
Via The Motley Fool · June 24, 2025
Amgen Expands Development Plans For Highly Anticipated Obesity Druginvestors.com
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via Investor's Business Daily · June 23, 2025
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analystsfool.com
Via The Motley Fool · June 21, 2025
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.fool.com
Via The Motley Fool · June 18, 2025
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?fool.com
Via The Motley Fool · June 16, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 10, 2025
1 Stock Down 34% This Year to Buy and Holdfool.com
Via The Motley Fool · June 8, 2025
Could Viking Therapeutics Become the Next Eli Lilly?fool.com
Via The Motley Fool · June 2, 2025
3 Best Growth Stocks to Buy in Junefool.com
Via The Motley Fool · June 2, 2025
Better Weight Loss Stock: Amgen or Viking Therapeutics?fool.com
Via The Motley Fool · May 22, 2025
Why Viking Therapeutics Stock Bumped 3% Higher Todayfool.com
Via The Motley Fool · May 16, 2025
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Priceinvestors.com
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Via Investor's Business Daily · May 16, 2025
Why Weight-Loss Developer Stocks Tumbled on Tuesdayfool.com
Via The Motley Fool · May 13, 2025
2 Monster Stocks in the Making to Buy Now and Hold for 10 Yearsfool.com
Via The Motley Fool · May 13, 2025
3 Monster Stocks in the Makingfool.com
Via The Motley Fool · May 11, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 9, 2025
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?fool.com
Via The Motley Fool · May 8, 2025
Why Viking Therapeutics Stock Surged Nearly 20% Higher in Aprilfool.com
Via The Motley Fool · May 6, 2025
Why Viking Therapeutics Stock Was Victorious This Weekfool.com
Via The Motley Fool · May 2, 2025
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Fridayfool.com
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Via The Motley Fool · May 2, 2025
Is Novo Nordisk Stock a Buy?fool.com
Via The Motley Fool · May 2, 2025